# LEGEND-T2DM Evidence Dissemination Summary

Target: **empagliflozin**, Comparator: **glipizide** Outcome: **Photosensitivity** Subgroup: **All**

How Often? (Incidence Rates from Target in PS-matched cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	17,766	13,442	6	0.45
Clinformatics	22,577	16,016	<5	<0.31
DA Germany	-	-	-	-
LDP France	-	-	-	-
MDCD	2,846	1,543	0	0.00
MDCR	1,995	1,146	<5	<4.36
Open Claims	267,140	198,708	32	0.16
Optum EHR	19,480	9,031	<5	<0.55
Veterans Affairs	19,568	17,578	<10	<0.57

How Reliable Are the Effect Estimates? (Objective Diagnostics from PS Matching)

What have we learned from the OHDSI Network? (composite estimates)